- THIS ARTICLE
-
Abstract
- Full Text (PDF)
- Alert me when this article is cited
- Alert me if a correction is posted
- SERVICES
- Similar articles in this journal
- Similar articles in PubMed
- Alert me to new issues of the journal
- Download to citation manager
- Reprints & Permissions
- CITING ARTICLES
- Citing Articles via HighWire
- Citing Articles via Google Scholar
- GOOGLE SCHOLAR
- Articles by Khalfan, W.
- Articles by Rose, M. D.
- Search for Related Content
- PUBMED
- PubMed Citation
- Articles by Khalfan, W.
- Articles by Rose, M. D.
Functional Interaction Between the PKC1 Pathway and CDC31 Network of SPB Duplication Genes
Waheeda Khalfan1,a, Irena Ivanovska1,a, and Mark D. Roseaa Department of Molecular Biology, Princeton University, Princeton, New Jersey 08544-1014
Corresponding author: Mark D. Rose, Department of Molecular Biology, Princeton University, Princeton, NJ 08544-1014., mrose{at}molbio.princeton.edu (E-mail)
Communicating editor: E. W. JONES
| ABSTRACT |
|---|
The earliest known step in yeast spindle pole body (SPB) duplication requires Cdc31p and Kar1p, two physically interacting SPB components, and Dsk2p and Rad23p, a pair of ubiquitin-like proteins. Components of the PKC1 pathway were found to interact with these SPB duplication genes in two independent genetic screens. Initially, SLG1 and PKC1 were obtained as high-copy suppressors of dsk2
rad23
and a mutation in MPK1 was synthetically lethal with kar1-
17. Subsequently, we demonstrated extensive genetic interactions between the PKC1 pathway and the SPB duplication mutants that affect Cdc31p function. The genetic interactions are unlikely to be related to the cell-wall integrity function of the PKC1 pathway because the SPB mutants did not exhibit cell-wall defects. Overexpression of multiple PKC1 pathway components suppressed the G2/M arrest of the SPB duplication mutants and mutations in MPK1 exacerbated the cell cycle arrest of kar1-
17, suggesting a role for the PKC1 pathway in SPB duplication. We also found that mutations in SPC110, which encodes a major SPB component, showed genetic interactions with both CDC31 and the PKC1 pathway. In support of the model that the PKC1 pathway regulates SPB duplication, one of the phosphorylated forms of Spc110p was absent in pkc1 and mpk1
mutants.
SACCHAROMYCES cerevisiae cells commit to a new round of cell division during G1. Activation of the G1-specific Cdc28p/cyclin complex promotes bud emergence, DNA replication, and duplication of the yeast microtubule organizing center, the spindle pole body (SPB; ![]()
![]()
![]()
The PKC1 cell integrity pathway has been implicated in numerous cellular processes including promoting bud emergence at the G1/S transition (![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
Although duplication of the SPB in G1 is also Cdc28p/Cln dependent, the specific signals that activate SPB duplication are unknown. The yeast SPB is a trilaminar disc-like structure embedded in the nuclear envelope from which nuclear and cytoplasmic microtubules are organized (![]()
![]()
![]()
![]()
Analysis of the early SPB duplication genes may give insight into how cell cycle control is exerted on SPB duplication because the G1 cell cycle machinery would be expected to target proteins required in the early stages of SPB duplication. Mutations in CDC31, the yeast homolog of centrin, block the earliest stage of SPB duplication, the formation of the satellite precursor (![]()
![]()
![]()
![]()
![]()
Another SPB component, Kar1p, is required at the same step of SPB assembly as Cdc31p (![]()
![]()
![]()
![]()
17 mislocalizes Cdc31p at high temperature and can be rescued by high dosage of CDC31 and the dominant allele CDC31-16. Formally, therefore, Kar1p functions upstream of Cdc31p. DSK2 is a nonessential ubiquitin-like protein identified as a dominant suppressor that also relocalizes Cdc31p in kar1-
17 mutants (![]()
![]()
![]()
![]()
rad23
strain is not defective for Cdc31p localization at the SPB. However, like kar1-
17 mutants, the SPB duplication defect of dsk2
rad23
can be suppressed by high-copy CDC31 and by CDC31-16. These results suggest that Dsk2p/Rad23p also function upstream of Cdc31p to mediate an important function of Cdc31p at the SPB (![]()
By employing the SPB duplication mutants kar1-
17 and dsk2
rad23
in different genetic screens, we identified multiple genetic interactions between the PKC1 and the SPB duplication pathways. Members of the PKC1 pathway, in high copy, could suppress the temperature sensitivity of kar1-
17, dsk2
rad23
, and cdc31-2. Overexpression of different members of the PKC1 pathway specifically suppressed the SPB duplication mutants but not other G2/M-arrested cells. In addition, we analyzed many combinations of double mutants and found extensive synthetic lethality and synthetic growth defects. To understand the functional basis of the synthetic interactions, we analyzed the phenotypes of the double mutants with respect to cell integrity and G2/M arrest. In a mpk1
kar1-
17 double mutant, the G2/M arrest defect was clearly exacerbated. We also found that phosphorylation of Spc110p, an essential SPB component, was defective in pkc1ts and mpk1
mutants, suggesting that the PKC1 pathway may directly or indirectly regulate Spc110p phosphorylation. Our results demonstrate an important functional link between PKC1 pathway activity and SPB duplication. We propose that PKC1 MAP kinase signaling positively regulates an SPB component, possibly to coordinate SPB duplication and bud emergence during G1.
| MATERIALS AND METHODS |
|---|
Microbial techniques and yeast strain construction:
Yeast media and microbial techniques were essentially as previously described (![]()
![]()
|
All yeast strains used are listed in Table 2. Yeast strains were constructed using standard genetic techniques. All yeast strains were isogenic to S288c. To generate double mutants for synthetic lethality studies, strains with mutations in cdc31-1, kar1-
17, spc10-220, mps2-1, and dsk2
rad23
were kept covered with a URA3 plasmid bearing the appropriate wild-type gene to prevent increased ploidy. PKC1 pathway components were then disrupted in the covered mutant strains. The resulting double mutant strains containing wild-type (WT) URA3 plasmids were streaked on 5-fluoroorotic acid (5-FOA) at 23o to select for plasmid loss (![]()
|
In most cases, double mutants between PKC1 pathway components and SPB duplication genes were generated either by PCR-mediated gene disruption (![]()
kar1-
17 strain (MY4646) was constructed by mating a kar1-
17 [KAR1 URA3] (MS2373) strain to a slg1
(MY4455), a cdc31-1 slg1
double mutant (MY6862) by crossing MY4455 to MY3885, the dsk2
rad23
slg1
(MY4916) strain by mating MY4449 to MY4455, the pkc1ts kar1-
17 strain (MY6805) by crossing DL523 (![]()
rad23
pkc1ts strain (MY6296) by mating DL523 (![]()
kar1-
17 synthetic lethality screen and identification of mpk1:
To identify mutations that result in synthetic lethality with kar1-
17, a "shuffle-mutagenesis" screening strategy was employed. MS2373 and MS2376, ura3 kar1-
17 strains of both mating types, were constructed, each carrying a KAR1 URA3-based centromeric plasmid to suppress the mutant defect. The strains were mutagenized with ethyl methanesulfonate (![]()
We cloned the wild-type gene corresponding to the SL6 mutation by complementation of the temperature sensitivity of kar1-
17 SL6 strain bearing the KAR1 LEU2 plasmid (MS5589) strain. MS5589 was transformed with a URA3 YCp50 library (![]()
kar1-
17 double mutant (MS5886) was generated, shown to be 5-FOA sensitive, and the 5-FOA sensitivity could be suppressed with a LEU2 MPK1 plasmid. To establish linkage, MS5831, a strain containing the SL6 mutation alone, was crossed to a mpk1
strain (MS5933). The resulting diploid strain was Ts-, indicating that mpk1
and SL6 fail to complement. Because a homozygous mpk1
diploid cannot sporulate, an MPK1 LEU2 plasmid was introduced into the diploid. Upon sporulation, all spores that did not contain the MPK1 LEU2 plasmid (43/43) were temperature sensitive, indicating that there were no wild-type recombinants. We concluded that MPK1 and SL6 are allelic because they are closely linked (<4.7 cM).
dsk2
rad23
high-copy suppressor screen:
Strain MY3592 was transformed with a YEp24 genomic library (![]()
![]()
, but not dsk2
, causes UV sensitivity, two plasmids that conferred UV resistance were deemed specific to rad23
and not studied further. To identify suppressors that were specific for SPB duplication, the plasmids were tested for their ability to suppress KAR1 and CDC31 mutations. Nine plasmids partially suppressed CDC31 mutations in an allele-specific manner. To identify the suppressing genes, we sequenced the ends of the library inserts using primers from the YEp24 vector. Two of them contained the SLG1 gene and were strong suppressors of both kar1-
17 and cdc31. One plasmid contained the PKC1 gene.
Microscopy:
To examine the G2/M arrest phenotype of the SPB duplication mutants, strains were grown at 23° to early logarithmic phase and one-half of the cultures were shifted to the indicated temperatures for 4-8 hr. To examine the nuclear morphology, 1 ml of each culture was collected by centrifugation and stained with 4',6-diamidino-2-phenylindole (DAPI) essentially as described (![]()
For cell cycle analysis of mpk1
kar1-
17, strain MS5886 was grown on 5-FOA at 23° for several days until small, slow-growing colonies appeared (incubation at lower temperatures failed to give any colonies). As a control, strain MS2373 was also grown on 5-FOA at 23°. The colonies arising on the 5-FOA plate were propagated in YPD liquid where the double mutant strain continued to grow very slowly compared to the control strain.
For live/dead analysis, strains were grown as described above. FUN-1 dye (![]()
Spc110 Western blot analysis:
Affinity-purified Spc110 antibodies were obtained from T. Davis (University of Washington, Seattle, WA) and crude Spc110 antibodies were obtained from Dr. Stirling (University of Dundee, Dundee, United Kingdom). Crude Spc110 antibodies were purified against a GST-Spc110p fusion (![]()
![]()
![]()
| RESULTS |
|---|
Overexpression of members of the PKC1/MPK1 pathway suppresses SPB duplication mutants:
Mutations in CDC31, KAR1, DSK2, and RAD23 result in defects at an early step during SPB duplication. Specifically, cdc31, kar1-
17, and dsk2
rad23
mutants arrest in G2/M as large-budded cells with a monopolar spindle and a single SPB (![]()
![]()
![]()
, rad23
, and kar1
17 mutants can be suppressed by high-copy CDC31, suggesting that Cdc31p is downstream in this pathway. To identify other genes that interact with the CDC31-related network of SPB duplication genes, we screened for high-copy suppressors of the temperature sensitivity of dsk2
rad23
(see MATERIALS AND METHODS). As expected, the most frequent high-copy suppressor was CDC31. In addition, we identified SLG1/WSC1 and PKC1, as partial suppressors of the growth defect of dsk2
rad23
at restrictive temperatures (Fig 1A). SLG1/WSC1 encodes a plasma membrane protein that signals to Pkc1p via Rho1p (![]()
![]()
![]()
![]()
![]()
|
To determine whether the suppression by high-copy SLG1 and PKC1 was relevant to SPB duplication, we examined their ability to suppress mutations in SPB components that show genetic interactions with dsk2
rad23
. As shown in Fig 1B and Fig C, high-copy SLG1 and PKC1 also partially suppressed kar1-
17 and cdc31-2. Two other alleles of CDC31, cdc31-1 and cd31-5, were not suppressed by any of the plasmids at any temperature (data not shown). We also tested whether the downstream components of the PKC1 pathway, BCK1-20 and MPK1 2µ, could suppress dsk2
rad23
, kar1-
17, and cdc31-2. As shown in Fig 1, BCK1-20 was a suppressor of kar1-
17 but not of the other mutations. High-copy MPK1 was a very weak suppressor of kar1-
17. All high-copy suppression results are summarized in Fig 1D. These results show that overexpression of multiple components of the PKC1 pathway can suppress mutations in all of the genes that are known to affect the first step in SPB duplication. Strikingly, the upstream components of the PKC1 pathway, PKC1 and SLG1, were consistently the strongest suppressors.
Slg1p suppresses the SPB duplication defects through Pkc1p:
High-copy SLG1 was a better suppressor of kar1-
17 than high-copy PKC1. On the other hand both were equally good suppressors of cdc31-2. We therefore wanted to determine whether SLG1 suppresses the SPB defects through PKC1 or via an independent pathway. We tested whether PKC1 lies downstream of SLG1 for suppression of SPB duplication mutants by asking whether high-copy PKC1 can suppress a dsk2
rad23
slg1
triple mutant. The triple mutant showed a stronger temperature-sensitive growth defect than the dsk2
rad23
double mutant. Nevertheless, high-copy PKC1 suppressed both the dsk2
rad23
slg1
triple mutant and the dsk2
rad23
double mutant well (Fig 2A). Therefore, Pkc1p does not require Slg1p to suppress dsk2
rad23
consistent with PKC1 being downstream of SLG1. We next tested whether Slg1p required Pkc1p for suppression. This experiment is complicated by the fact that PKC1 is an essential gene. We therefore determined whether high-copy SLG1 could suppress a dsk2
rad23
pkc1ts triple mutant. Once again, the temperature sensitivity of the dsk2
rad23
pkc1ts mutant was more severe than that of either dsk2
rad23
or pkc1ts. We found that high-copy SLG1 did not suppress the dsk2
rad23
pkc1ts triple mutant at 37° (Fig 2B), consistent with Slg1p being upstream of Pkc1p's essential function. However, we found that, at an intermediate temperature of 32°, high-copy SLG1 did suppress the dsk2
rad23
pkc1ts triple mutant as well as DSK2 (Fig 2B). This result can be interpreted in two ways. First, the pkc1ts allele may be partially active at 32°, and high-copy SLG1 may be suppressing by enhancing the partial activity. Alternatively, suppression at 32° may be due to a function of Slg1p that is partially independent of Pkc1p.
|
Overexpression of Pkc1p pathway components does not suppress G2/M-arrested mutants in general:
The SPB duplication mutations that showed genetic interactions with the PKC1 pathway cause a G2/M arrest at the restrictive temperature. Therefore, we considered the possibility that the PKC1 pathway may simply be required for maintaining the integrity of large-budded cells at G2/M. If so, activation of the pathway may simply suppress the growth defect of SPB mutants by suppressing the loss of viability of G2/M-arrested cells. To address this possibility, we examined whether high-dosage SLG1 or PKC1 could rescue the temperature sensitivity of a variety of mutants that arrest at G2/M through different mechanisms. We examined cdc13-1, defective for telomere metabolism (![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
|
Another trivial possibility is that overexpression of PKC1 pathway components suppresses SPB duplication mutants by extending the length of G1 and thereby allowing extra time for SPB duplication to occur. To test this possibility, we monitored cell cycle progression in strains either overexpressing or deleted for PKC1 pathway components after release from various synchronizations. We found that in all cases the cells proceeded through the cell cycle with equivalent kinetics (![]()
SPC110 is genetically linked to the CDC31 network of SPB duplication genes:
Strikingly, the spc110-220 mutant strain was strongly suppressed by high-copy PKC1 and SLG1 (Fig 3). This observation raised the possibility that Spc110p may have functions related to those of Kar1p, Cdc31p, or Dsk2p and Rad23p. Spc110p is a component of the inner SPB plaque that binds calmodulin (![]()
![]()
![]()
![]()
17 and dsk2
rad23
, we asked whether spc110-220 could be suppressed by high-copy CDC31 or CDC31-16, known suppressors of dsk2
rad23
and kar1-
17 (![]()
![]()
17. These results suggest that Cdc31p also interacts with Spc110p in vivo, consistent with the in vitro data. In summary, increased dosage of Pkc1p and Slg1p suppressed all four mutations that can be suppressed by high-copy Cdc31p. These findings suggest that the PKC1 pathway interacts with one or several proteins in the Cdc31p SPB assembly network.
|
Mechanism of high-dosage suppression:
We next wanted to investigate how high-dosage SLG1 and PKC1 suppressed the growth defect of the SPB mutants. The simplest model is that the PKC1 pathway contributes to SPB function. However, the PKC1 pathway has a well-established role in cell-wall integrity. Therefore, there is a formal possibility that genes in the CDC31 network play an additional role in cell-wall integrity and that these SPB mutants suffer cell-wall defects that can be suppressed by SLG1 and PKC1. The compromised cell walls in PKC1 pathway mutants cause cell lysis and death. We therefore tested whether the kar1-
17 and dsk2
rad23
mutants exhibited cell lysis, using FUN-1, a fluorescent viability probe (![]()
rad23
and kar1-
17 strains at the restrictive temperature (8 and 16% respectively) and these were not affected by high-copy SLG1 or high-copy PKC1 (Table 3). These results indicate that decreased lysis/cell death is not likely to be the mechanism by which SLG1 and PKC1 suppress the SPB duplication mutants.
|
We next tested whether high-dosage SLG1 and PKC1 suppressed the G2/M arrest of kar1-
17, dsk2
rad23
, and spc110-220 mutants, caused by the failure in SPB duplication. The G2/M arrest is demonstrated by large-budded cells with a single nucleus, indicating failure of the duplicated DNA to segregate. If high-dosage SLG1 and PKC1 suppressed the SPB duplication defects of the mutants, we would expect a decrease in the percentage of G2/M-arrested cells. Indeed, SLG1 and PKC1 overexpression partially suppressed the G2/M arrest defect of kar1-
17 at 35° (from 44 to 30%) and SLG1 overexpression partially suppressed at 37° (from 40 to 23%) (Table 4), consistent with the partial suppression of the temperature sensitivity of kar1-
17. Similarly, the G2/M defect of dsk2
rad23
was partially suppressed by high-copy SLG1 at 37° (from 71 to 44%; Table 4). Moreover, high-copy PKC1 suppressed the G2/M arrest phenotype of spc110-220 (from 76 to 36%). Therefore, SLG1 and PKC1 partially suppressed the G2/M arrest of kar1-
17, dsk2
rad23
, and spc110-220 mutants, implying that they suppress the SPB duplication defects. Our findings support the idea that SLG1 and PKC1 provide a positive function for SPB duplication.
|
Synthetic lethal interactions between SPB duplication mutants and multiple members of the PKC1 pathway:
If the Pkc1p pathway does regulate SPB duplication, then PKC1 pathway mutations should be partially compromised for SPB duplication. If so, their function should be revealed by synthetic lethal interactions with the relevant SPB mutants. In an independent genetic screen, we identified mutations in MPK1, the PKC1 pathway MAP kinase, as being synthetically lethal with kar1-
17 (see MATERIALS AND METHODS). In Fig 5A, we demonstrate synthetic lethality by the inability of a strain to segregate a URA3-based plasmid containing a wild-type copy of one of the genes mutated on the chromosome. kar1-
17 and mpk1
all grew on 5-FOA, a wild-type control, at 23°. In contrast, the mpk1
kar1-
17 double mutant strain was extremely sensitive to 5-FOA because of a requirement for the KAR1 URA3 plasmid for survival. Thus, the mpk1
kar1-
17 double mutant combination is synthetically lethal.
|
We next asked whether the synthetic lethality observed between mpk1 and kar1-
17 could be extended to other SPB components and members of the PKC1 pathway. First, to test whether other SPB mutants showed synthetic lethal interactions with mpk1
, we deleted MPK1 in the dsk2
rad23
, cdc31-1, and spc110-220 mutant strains containing the appropriate wild-type gene on URA3 plasmids. The mpk1
was synthetically lethal with dsk2
rad23
and spc110-220 mutations (Fig 5A). The cdc31-1 mpk1
double mutant showed a greatly exacerbated growth defect at temperatures permissive for either single mutant (Fig 5B). In contrast, the mps2-1 mpk1
double mutant did not show a synthetic lethal phenotype (Fig 5A) confirming that the synthetic lethal interactions are restricted to the CDC31 network of SPB duplication genes. In summary, all the CDC31-related SPB mutants analyzed showed either synthetic lethality or synthetic growth defects when MPK1 was deleted.
Next, we tested whether mutations in other components of the PKC1 pathway showed synthetic lethal interactions with the SPB duplication mutants. All the double mutant combinations tested showed synthetic lethality or severely exacerbated growth defects (Fig 5A and Fig B). In particular, the bck1
kar1-
17 double mutant was synthetically lethal, while the other combinations had restrictive temperatures lower than either parent. Fig 5C summarizes all of the exacerbated growth defects and synthetic lethal interactions observed. On the basis of both high-dosage suppression and synthetic lethal genetic interactions, we conclude that the PKC1 pathway provides a function that is crucial for survival of the SPB duplication mutants.
Characterization of the double mutants:
The genetic interactions presented thus far do not distinguish whether the synthetic defects affect SPB duplication per se. Although this seems most likely, an alternative is that mutations in SPB components could have secondary defects in cell integrity that are exacerbated in the absence of the PKC1 pathway. To assess the nature of the synthetic defects directly, we analyzed the phenotypes of the double mutant strains. This analysis is technically compromised by the fact that the terminal phenotype associated with a defect in SPB duplication (arrest at G2/M with a large bud and an unduplicated SPB) requires an extended period of bud growth. Bud growth is extremely sensitive to defects in the PKC1 pathway causing cells to lyse before the large bud stage. Thus, at the restrictive temperature, most double mutants arrested as a mixture of small-budded and large-budded cells and so were not informative as to whether there was an increase in the SPB duplication defect (data not shown). Synchronizing the cultures in G1 with
-factor, followed by release from arrest, did not alleviate the problem (data not shown). However, mpk1
exhibited a strong synthetic lethality with kar1-
17 at a temperature where the single mutant did not lyse (Table 5). A slow-growing mpk1
kar1-
17 mutant propagated at 23° showed an increase in G2/M-arrested cells (53%) relative to the kar1-
17 single mutant (33%) without showing an elevated frequency of dead cells (Table 5). Thus, this double mutant showed an increase in G2/M arrest, consistent with the hypothesis that the PKC1 pathway plays a positive role in SPB duplication.
|
Pkc1p pathway activity is required for proper Cdc31p function in vivo:
The genetic interactions suggest that Pkc1p pathway activity is required for optimal function of SPB duplication genes. All of the genes suppressed by PKC1 overexpression can also be suppressed by high-copy CDC31. Therefore, we next asked whether the PKC1 pathway is required for Cdc31p to suppress the SPB mutations. Specifically, we tested whether high-copy CDC31 and the dominant alleles CDC31-16 and DSK2-1 could suppress kar1-
17 in the absence of the Pkc1p pathway component Slg1p. The dominant alleles CDC31-16 and DSK2-1, but not high-copy CDC31, can suppress a complete deletion of KAR1 (![]()
17 as well as KAR1 (Fig 6, top). Previous analysis has failed to uncover any mutations that compromise the ability of CDC31-16 and DSK2-1 to suppress kar1-
17 (W. KHALFAN and M. ROSE, unpublished observations; ![]()
kar1-
17 as well as KAR1 at 37°. Moreover, high-copy CDC31 completely failed to suppress the double deletion even at 30° (Fig 6, bottom). These results can be interpreted in two ways. First, Slg1p may be required for optimal function of Cdc31p. By this scheme the PKC1 pathway would lie upstream or in a parallel pathway leading to activation of Cdc31p. Alternatively, Cdc31p itself may be required to activate the PKC1 pathway. In this scenario, the PKC1 pathway would lie downstream of Cdc31p, and mutations in cdc31 and the other SPB duplication genes would be predicted to alter PKC1 pathway activity. We tested this second idea by measuring PKC1 pathway activity in the SPB duplication mutants in a number of ways. First, as a measure of MKK1 and MKK2 activity, we tested whether MPK1 was phosphorylated in a kar1-
17 strain upon mild heat shock treatment (![]()
![]()
17 strain (data not shown). We also examined the in vitro kinase activity of Pkc1p immunoprecipitated from a kar1-
17 strain, using myelin basic protein (MBP) as the substrate (![]()
![]()
17 strain, this was a general effect of G2/M arrest, since another G2/M mutant, cdc13, also showed reduced levels of Rlm1p transcriptional activity. Taken together, it seems unlikely that the CDC31 pathway activates the PKC1 pathway. We therefore interpret the inability of high-copy CDC31 to suppress the kar1-
17 slg1
double mutant (Fig 6) as being due to reduced activity or levels of Cdc31p in the slg1
mutant. The observation that CDC31-16 and DSK2-1, but not high-copy CDC31, could partially suppress the kar1-
17 slg1
double mutant at 37° suggests that the dominant suppressors may act by a different mechanism that is partially independent of the PKC1 pathway. In support of the idea that they act differently, CDC31 2µ, but not CDC31-16, suppressed the temperature-sensitive growth defect of spc110-220 (Fig 4).
|
Phosphorylation of Spc110p is defective in pkc1ts and mpk1
mutants:
We next sought to explore the molecular mechanism by which the PKC1 pathway affects SPB duplication. One possibility is that the PKC1 pathway phosphorylates an SPB component. On the basis of the genetic interactions, possible candidates include Kar1p, Cdc31p, and Spc110p. We first examined Kar1p in the different PKC1 pathway mutants and found no change in the mobility of various Kar1p forms (data not shown). We next tested Spc110p, which exists as at least two distinct phosphorylated forms of molecular weights 112 kD and 120 kD. The 120-kD form (p120) arises from additional serine/threonine phosphorylation of the 112-kD form and is cell cycle regulated, predominating in small-budded cells with duplicated DNA and short spindles (![]()
![]()
![]()
cultures grown in YPD at 30° and shifted to 37° for 3 hr. An asynchronous wild-type culture grown at 37° contained both p120 and p112 forms,
-factor-arrested wild-type strain contained the faster migrating p112 form, and nocodazole-arrested wild-type cells contained the p120 form (Fig 7 and ![]()
![]()
culture showed reduced levels of p120 at permissive temperature (30°) and drastically reduced levels of p120 at 37°.
|
The disappearance of the p120 form in pkc1ts and mpk1
strains is not likely to be due to the accumulation of cells at a stage in the cell cycle prior to Spc110p phosphorylation. First, although the pkc1ts mutant accumulates small-budded cells, the small-budded cells have already initiated DNA replication and formed short spindles (![]()
![]()
mutant, the strain did not arrest at any particular stage of the cell cycle at the restrictive temperatures. We directly examined the cell cycle distribution of pkc1ts and mpk1
strains from aliquots taken at the time of protein extract preparation. As shown in Table 6, while there were differences in their cell cycle distribution compared to wild type, the distribution was not correlated with the presence or absence of the p120 form. These results suggest that the lack of phosphorylation is not due to a block in cell cycle progression. Taken together, our results suggest that Pkc1p and/or Mpk1p may directly or indirectly phosphorylate Spc110p. These results may provide a mechanistic basis for the genetic interactions between thePKC1 pathway and SPB duplication genes.
|
Swi4p but not Rlm1p function is required in SPB duplication mutants:
Having established that Pkc1p and the MAP kinase module affect SPB duplication, we wanted to identify the downstream effectors of the PKC1 pathway that transduce the signal to the SPB. One well-established downstream target of Mpk1p is Rlm1p, a MADS-box family transcription factor whose activity is MPK1 dependent (![]()
![]()
![]()
, deletion of RLM1 does not result in cell morphogenesis and/or lysis defects, indicating that there must be additional downstream effectors of MPK1 activity. The transcription factor complex consisting of Swi4p/Swi6p (SBF) has also been suggested to be a second downstream effector of MPK1 (![]()
![]()
![]()
![]()
![]()
![]()
17 rlm1
and kar1-
17 swi4
double mutants containing KAR1 URA3 plasmids and examined their ability to lose the plasmid on 5-FOA at a range of temperatures. As shown in Fig 8A, we found that the kar1-
17 swi4
strain was synthetically lethal, similar to the kar1-
17 mpk1
double mutant. In contrast, the kar1-
17 rlm1
double mutant did not grow any more poorly than either single mutant alone at a range of temperatures (Fig 8B). Since the cdc31-1 mpk1
double mutant also has a severe growth defect, we examined whether cdc31-1 mutants were sensitive to mutations in either SWI4 or RLM1. Similar to the results obtained with the kar1-
17 swi4
double mutant, a cdc31-1 swi4
double mutant was synthetically lethal, whereas a cdc31-1 rlm1
double mutant did not show any synthetic growth defects (Fig 8C and Fig D). These results argue that Swi4p's function is crucial for survival of the SPB duplication mutants, kar1-
17 and cdc31-1, in activating the PKC1 pathway and/or transmitting a signal downstream of Mpk1p. Clearly however, Rlm1p is not the target of Mpk1p activity that is relevant for SPB duplication.
|
Because Swi4p might mediate its effects through transcriptional regulation, and because Cdc31p function is compromised in the kar1-
17 slg1
mutant (Fig 6), one possible explanation for the genetic interactions would be if the PKC1 pathway regulated CDC31 transcription. To address this question, we examined the levels of CDC31 mRNA in asynchronously growing wild-type, pkc1ts, mpk1
, and swi4
mutants either at 23° or 37°. We found that the levels of CDC31 mRNA were similar in the mutant and wild-type strains (data not shown). We also found the levels of Cdc31p protein in pkc1ts mutant to be comparable to that of wild type at 37°. In addition, the levels of Kar1p and Spc110p were wild type in pkc1ts and mpk1
strains (data not shown). Therefore, it is unlikely that the PKC1 pathway regulates the synthesis of Cdc31p, Kar1p, or Spc110p. It remains possible, however, that the expression of an unidentified SPB component is regulated by the PKC1 pathway.
| DISCUSSION |
|---|
Genetic interactions with SPB duplication genes suggest a role for the PKC1 pathway in SPB duplication:
We identified numerous genetic interactions between SPB duplication genes in the CDC31 pathway and the PKC1 signal transduction cascade. Overexpression of SLG1 or PKC1 partially rescued the temperature sensitivity of dsk2
rad23
, kar1-
17, and cdc31-2. We assume that overexpression leads to activation of the PKC1 pathway. The suppression was specific to SPB duplication defects and was not due to general suppression of G2/M arrest. High-dosage SLG1 and PKC1 did not simply rescue cell-wall-related defects of the SPB mutants, because we did not find significant cell lysis in dsk2
rad23
and kar1-
17. It is interesting that the most upstream members of the PKC1 pathway, SLG1 and PKC1, were the strongest suppressors. We present two interpretations of this observation. First, the PKC1 pathway may branch at one or more points and the different components of the PKC1 pathway may suppress the SPB duplication mutants by different mechanisms. Alternatively, consistent with the observations of other researchers, overexpression of upstream components may activate the PKC1 pathway more strongly than overexpression of downstream components, resulting in different levels of suppression of the SPB duplication mutants (![]()
We also observed somewhat different behaviors among the different PKC1 pathway components in our synthetic lethal analyses. The severity of the interactions was the reverse of the suppression, with the most downstream components showing the most severe synthetic phenotypes in combination with SPB duplication mutations. The SPB mutants were particularly sensitive to mutations in MPK1. With the exception of cdc31, all the SPB mutants showed synthetic lethality with mpk1
, while mutations in the other PKC1 pathway genes resulted in viable strains with more severe growth defects. In addition, the mpk1
kar1-
17 double mutant had an exacerbated G2/M arrest phenotype, suggesting a requirement for the MPK1 gene in SPB duplication. It is possible that Mpk1p is crucial for the survival of SPB mutants because it is targeted and activated by other MAP kinase signaling pathways, especially in the absence of upstream components of the PKC1 pathway. The presence of such cross-talk may help to explain why mutations in upstream components do not exacerbate the growth defect of SPB duplication mutants as severely as mutations in MPK1.
The SPB mutants cdc31 and kar1 showed synthetic lethality with swi4
arguing that, like Mpk1p, Swi4p is also crucial for the survival of the SPB duplication mutants. The Swi4p/Swi6p transcription factor complex (SBF) is a proposed target of Mpk1p (![]()
![]()
clearly rule out the possibility that Rlm1p is the important target of Mpk1p in the SPB duplication mutants. Recently, a genome-wide ana







